<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">3. Discussion</segment>
<segment id="2" parent="1002" relname="span">Synthetic lethality has immense potential in cancer therapeutics .</segment>
<segment id="3" parent="1004" relname="circumstance">Where the driver genes or oncogenes cannot be targeted ,</segment>
<segment id="4" parent="1004" relname="span">synthetic lethal interactors can potentially serve as drug targets in the presence of mutations in the driver genes ,</segment>
<segment id="5" parent="4" relname="circumstance">as the mutant tumor cells are dependent upon the synthetic lethal interactors for their survival .</segment>
<segment id="6" parent="1006" relname="span">Recent advances in RNAi and CRISPR technologies have enabled large-scale synthetic lethality screens for individual genes</segment>
<segment id="7" parent="6" relname="purpose">to be performed in human cell lines .</segment>
<segment id="8" parent="1009" relname="span">The genetic dependency map</segment>
<segment id="9" parent="8" relname="restatement">( DepMap )</segment>
<segment id="10" parent="1010" relname="span">project is dedicated</segment>
<segment id="11" parent="10" relname="circumstance">towards finding genetic dependencies from the published shRNA/CRISPR or drug screening data in cancer cell lines .</segment>
<segment id="12" parent="1012" relname="preparation">While identifying genetic dependencies or essentiality in the context of specific genetic alterations is important</segment>
<segment id="13" parent="1013" relname="preparation">for screening potential targets for cancer therapy ,</segment>
<segment id="14" parent="1014" relname="preparation">identification of clinically relevant synthetic lethal pairs in cancers has been a challenge .</segment>
<segment id="15" parent="1017" relname="span">A recent work tried to address this limitation with an in silico analysis of clinical relevance of the SL interactions</segment>
<segment id="16" parent="15" relname="elaboration">identified from in vitro SL screens</segment>
<segment id="17" parent="1019" relname="attribution">and reported</segment>
<segment id="18" parent="1019" relname="span">that only a fraction of these SL interactions hold up to be clinically significant</segment>
<segment id="19" parent="18" relname="circumstance">when tested on TCGA tumor data .</segment>
<segment id="20" parent="1014" relname="joint">Also , these in vitro screens are costly</segment>
<segment id="21" parent="1014" relname="joint">and finding synthetic lethal interactors for many cancer genes remain challenging .</segment>
<segment id="22" parent="1022" relname="span">SL-BioDP addresses such problems</segment>
<segment id="23" parent="1023" relname="span">by using a computational method</segment>
<segment id="24" parent="1024" relname="span">that leverages the available cancer genetic data resources</segment>
<segment id="25" parent="1025" relname="joint">to predict synthetic lethal partners of all cancer susceptibility genes</segment>
<segment id="26" parent="1025" relname="joint">and assesses the clinical relevance from matched clinical data .</segment>
<segment id="27" parent="1027" relname="span">The computational predictions of SL interactions were subjected to extensive in silico validation</segment>
<segment id="28" parent="27" relname="means">using either published literature or shRNA and drug screening data from cancer cell lines .</segment>
<segment id="29" parent="1029" relname="span">SL-BioDP is a comprehensive resource for the query and visualization of cancer-specific synthetic lethality and potential drug targets</segment>
<segment id="30" parent="29" relname="elaboration">based on the concept of synthetic lethality .</segment>
<segment id="31" parent="1031" relname="span">The utility of this web tool is that it enables multilevel querying</segment>
<segment id="32" parent="31" relname="elaboration">based on cancer genes , tissues , or drugs of interest .</segment>
<segment id="33" parent="1033" relname="span">In contrast to the other database resources on synthetic lethality , SL-BioDP enables assessment of the clinical relevance</segment>
<segment id="34" parent="33" relname="elaboration">of targeting the SL interactor gene in the presence of mutation in the primary gene .</segment>
<segment id="35" parent="1037" relname="span">The prediction of drug response</segment>
<segment id="36" parent="35" relname="elaboration">depending on the presence of mutations in the primary genes</segment>
<segment id="37" parent="1036" relname="same_unit">is another important feature</segment>
<segment id="38" parent="1036" relname="elaboration">added in SL-BioDP .</segment>
<segment id="39" parent="1040" relname="span">Our analysis of published drug screening data and gene mutation data from matched cancer cell lines identified known synthetic lethality-based drug targets like sensitivity of the drug , olaparib</segment>
<segment id="40" parent="39" relname="elaboration">( PARP inhibitor )</segment>
<segment id="41" parent="1039" relname="same_unit">in the presence of mutation in the BRCA1 gene , and in general the homologous recombination repair pathway .</segment>
<segment id="42" parent="1032" relname="joint">In addition , the analysis offers to look into new potentially effective gene mutation-based drug therapies .</segment>
<segment id="43" parent="1043" relname="span">We extended our analysis</segment>
<segment id="44" parent="1044" relname="span">to infer potential synergy between drugs</segment>
<segment id="45" parent="44" relname="elaboration">targeting the predicted SL interactors .</segment>
<segment id="46" parent="1046" relname="attribution">We reasoned</segment>
<segment id="47" parent="1047" relname="span">that if the presence of a mutation</segment>
<segment id="48" parent="47" relname="elaboration">( or loss of function )</segment>
<segment id="49" parent="1048" relname="joint">in a primary gene makes cancer cells sensitive to certain drugs</segment>
<segment id="50" parent="1048" relname="joint">targeting an SL interactor ,</segment>
<segment id="51" parent="1051" relname="span">then it is highly likely that the drugs</segment>
<segment id="52" parent="1052" relname="span">targeting the primary gene will also make the cancer cells sensitive to those drugs</segment>
<segment id="53" parent="52" relname="elaboration">targeting the SL interactor .</segment>
<segment id="54" parent="1054" relname="span">These inferred drug synergies can be searched in SL-BioDP for each of the 18 tumor histologies</segment>
<segment id="55" parent="54" relname="elaboration">included in SL-BioDP .</segment>
<segment id="56" parent="1056" relname="span">In support of our predictions of synergistic drugs in cancers , we collected literature references and reports of ongoing clinical trials ,</segment>
<segment id="57" parent="56" relname="elaboration">which is included in Supplementary Table S3 .</segment>
<segment id="58" parent="1057" relname="span">Combined together , SL-BioDP can serve as a comprehensive tool ,</segment>
<segment id="59" parent="1058" relname="span">for exploring potentially actionable mutation-based targeted therapies</segment>
<segment id="60" parent="1059" relname="span">based on the concept of synthetic lethality ,</segment>
<segment id="61" parent="60" relname="elaboration">that shows possible clinical relevance .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1005" relname="background"/>
<group id="1003" type="span" parent="2" relname="elaboration"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1005" type="multinuc" parent="1001" relname="span"/>
<group id="1006" type="span" parent="1005" relname="joint"/>
<group id="1007" type="multinuc" parent="1005" relname="joint"/>
<group id="1008" type="multinuc" parent="1007" relname="sequence"/>
<group id="1009" type="span" parent="1008" relname="same_unit"/>
<group id="1010" type="span" parent="1008" relname="same_unit"/>
<group id="1011" type="span" parent="1007" relname="sequence"/>
<group id="1012" type="span" parent="1011" relname="span"/>
<group id="1013" type="span" parent="1012" relname="span"/>
<group id="1014" type="multinuc" parent="1013" relname="span"/>
<group id="1017" type="span" parent="1014" relname="joint"/>
<group id="1018" type="span" parent="1014" relname="joint"/>
<group id="1019" type="span" parent="1018" relname="span"/>
<group id="1022" type="span" parent="1014" relname="joint"/>
<group id="1023" type="span" parent="22" relname="means"/>
<group id="1024" type="span" parent="23" relname="elaboration"/>
<group id="1025" type="multinuc" parent="24" relname="purpose"/>
<group id="1027" type="span" parent="1014" relname="joint"/>
<group id="1029" type="span" parent="1014" relname="joint"/>
<group id="1030" type="span" parent="1014" relname="joint"/>
<group id="1031" type="span" parent="1032" relname="preparation"/>
<group id="1032" type="multinuc" parent="1030" relname="span"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1035" type="span" parent="1032" relname="joint"/>
<group id="1036" type="multinuc" parent="1035" relname="span"/>
<group id="1037" type="span" parent="1036" relname="same_unit"/>
<group id="1039" type="multinuc" parent="1032" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="same_unit"/>
<group id="1042" type="multinuc" parent="1032" relname="joint"/>
<group id="1043" type="span" parent="1042" relname="sequence"/>
<group id="1044" type="span" parent="43" relname="purpose"/>
<group id="1045" type="span" parent="1042" relname="sequence"/>
<group id="1046" type="multinuc" parent="1045" relname="span"/>
<group id="1047" type="span" parent="1046" relname="same_unit"/>
<group id="1048" type="multinuc" parent="1046" relname="same_unit"/>
<group id="1051" type="span" parent="1048" relname="joint"/>
<group id="1052" type="span" parent="51" relname="elaboration"/>
<group id="1054" type="span" parent="1048" relname="joint"/>
<group id="1056" type="span" parent="1048" relname="joint"/>
<group id="1057" type="span" parent="1048" relname="joint"/>
<group id="1058" type="span" parent="58" relname="purpose"/>
<group id="1059" type="span" parent="59" relname="elaboration"/>
	</body>
</rst>
